Clinical Trial Update: Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety, tolerability, and efficacy of AZD5363 combined with paclitaxel in advanced/metastatic breast cancer (ER-positive) completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD5363 (capivasertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-04-01